Vaximm Is A Privately Heldswiss German Biotech Company That Is Developing Oral T Cell Immunotherapies For Patients Suffering From Cancervaximm S Product Platform Is Based On A Live Attenuatedsafeorally Available Bacterial Vaccine Strainwhich Is Modified To Stimulate Patientscytotoxic T Cells To Target Specific Structures Of The Tumorthe Company Has A Pipeline Of Complementary Development Candidates Targeting Different Tumor Structures Lead Product Candidateoral Vxm01Activates Killer Cells Targeting Tumor Specific Vasculature And Certain Immune Suppressive Cellsthereby Increasing Immune Cell Infiltration In Solid Tumorsvxm01 Is Currently In Clinical Development For Several Tumor Typesincluding Brain Cancervaximm Has Completed A Clinical Trial Evaluating Vxm01 In Combination With The Human Anti Pd L1 Antibodyavelumabas Part Of A Scientific Collaboration With Merck Kgaadarmstadtgermany Vaximm Also Has A Collaboration Agreement With China Medical System Holdingscms Granting Cms Full Rights In China And Other Asian Countriesexcluding Japanto Vaximm S Existing Programsvaximm Ag Is Headquartered In Baselswitzerlandits Wholly Owned Subsidiaryvaximm Gmbhlocated In Mannheimgermanyis Responsible For The Company S Development Activities
No conferences found for this company.
| Company Name | Vaximm Gmbh |
| Country |
Germany
|
| Address | N/A |
| Telephone | N/A |
| N/A |
